Results 71 to 80 of about 13,452 (195)

Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo

Pharmaceuticals, 2018
Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with 177Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs.
Tais Basaco, Stefanie Pektor, Josue M. Bermudez, Niurka Meneses, Manfred Heller, José A. Galván, Kayluz F. Boligán, Stefan Schürch, Stephan von Gunten, Andreas Türler, Matthias Miederer   +10 more
doaj   +1 more source

Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in Vitro and in Vivo in human renal cell carcinoma xenografts [PDF]

, 1997
Shoucheng Ning, Kirk Trisler, Barry W. Wessels, Susan J. Knox   +3 more
openalex   +1 more source

Experimental and clinical approaches to a radioimmunotherapy in o

Сибирский онкологический журнал, 2016
Molecular nuclear medicine plays an important role in the diagnosis and therapy of cancer. Radioimmunodetection and radioimmunotherapy (RIT) involve the use of antibodies conjugated with diagnostic or therapeutic radionuclides, respectively.
E. V. Abakushina, D. N. Abakushin, Ju. N. Anohin   +2 more
doaj  

Radioimmunotherapy of experimental pancreatic cancer with 131I‐labeled monoclonal antibody PAM4 [PDF]

, 1997
David V. Gold, Thomas M. Cardillo, Yehuda Vardi, Rosalynn Blumenthal   +3 more
openalex   +1 more source

Targeting Cancer Stem Cells with Radioimmunotherapy: The Case of the Ovarian Cancer Stemness-Associated Biomarker L1CAM

International Journal of Translational Medicine
Cancer stem cells (CSCs) are a dynamic population of tumor cells characterized by long-term self-renewal, high tumorigenicity, resistance to conventional therapies such as radio- and chemotherapy, and capacity to recapitulate the tumor heterogeneity ...
Tihomir Zh. Todorov, Roger Schibli, Martin Béhé, Jürgen Grünberg   +3 more
doaj   +1 more source

Enhanced Efficacy of Radioimmunotherapy Combined with Systemic Chemotherapy and Local Hyperthermia in Xenograft Model [PDF]

, 2000
Seigo Kinuya, Kunihiko Yokoyama, Shota Konishi, Takashi Hiramatsu, Naoto Watanabe, Noriyuki Shuke, Tamio Aburano, Teruhiko Takayama, Takatoshi Michigishi, Norihisa Tonami   +9 more
openalex   +1 more source

Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma

Exploration of Targeted Anti-tumor Therapy
Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventional treatment.
Hiroki Goto, Yoshioki Shiraishi, Seiji Okada   +2 more
doaj   +1 more source

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts [PDF]

, 2001
Oliver W. Press, Melissa C. Corcoran, Krishnan Subbiah, Don K. Hamlin, D. Scott Wilbur, Timothy A. Johnson, Louis Theodore, Eric Kin Cheong Yau, Robert W. Mallett, Damon L. Meyer, Don B. Axworthy   +10 more
openalex   +1 more source

Rationales, evidence, and design considerations for fractionated radioimmunotherapy [PDF]

, 2002
Gerald L. DeNardo, J Schlom, Donald J. Buchsbaum, Ruby F. Meredith, Joseph A. O’Donoghue, George Sgouros, John L. Humm, Sally J. DeNardo   +7 more
openalex   +1 more source

A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection [PDF]

, 2002
Aiden Flynn, Alan J. Green, R. Barbara Pedley, Geoffrey M. Boxer, Jason L.J. Dearling, Rebecca Watson, R Boden, Richard H. J. Beǵent   +7 more
openalex   +1 more source